Company News TheraMab
29 March 2016
TheraMAB Company has successfully participated in a prestigious start-ups contest at Falling Walls Conference: The International Conference on Future Breakthroughs in Science and Society, Berlin, Germany.
November, 2015 The TheraMAB Company has participated in a start-ups contest at the Falling Walls Conference held in Berlin (Germany) from 8th to 9th November 2015.
25 December 2014
Moscow, Russia, December 2014. Theramab presents new data on theralizumab published in Nature Biotechnology special issue Biopharma Dealmakers.
14 January 2014
TheraMAB LLC. announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis
Moscow, Russia, January 2014. "TheraMAB" LLC. announces the beginning of multicenter Phase Ib/IIa clinical trial of multiple TAB08 i.v. administration. This is “first-in-class” anti-CD28 humanized mAb of IgG4 type for the treatment of patients with autoimmune diseases.
20 March 2012
Moscow, Russia, March, 2012. "TheraMAB" has announced the closing of its 2nd venture investment tranche of RUB 157 million.
19 November 2011
"TheraMAB" LLC. launches Phase I clinical trial of "first-in-class" agonistic monoclonal antibody TABO8 in Russia
Moscow, Russia, November, 2011. "TheraMAB" announced an important step in TAB08 development: the first volunteer was enrolled in the phase I clinical trial, a humanized antibody for the treatment of autoimmune diseases and hemo-oncological disorders.
18 August 2011
August, 18, 2011, TheraMAB LLC. earned the resident status at the business and innovation center of “Skolkovo” Fund at the inauguration ceremony in Gorky Central Park of Culture and Leisure.
16 September 2009
Moscow, Russia, September, 2009. "TheraMAB" has announced the closing of its 1st venture investment tranche of RUB 192 million.